San Diego biotechs raise $143M.
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Verus Pharmaceuticals
|
$78M/$20M loan
|
Domain Associates, Prospect Venture Partners |
Verus plans to in-license pediatric drugs and move quickly to Phase III. |
|
Somaxon Pharmaceuticals
|
$65M
|
MPM Capital Partners |
Somaxon has an insomnia drug -- Silenor -- in Phase III. |
|
Osiris Therapeutics
|
$50M
|
Friedli Corporate |
Osiris is in a race to become the first biotech to commercialize stem cell products. |
|
Ziopharm
|
$18.1M
|
Paramount BioCapital |
Ziopharm is looking to in-license cancer products. |